Oral typhoid vaccine. Acambis/Berna.
Acambis and Berna are developing HolaVax-Typhoid, a single-dose, live attenuated oral vaccine for the potential prophylaxis of typhoid. A phase II trial was successfully completed in January 1999, and in September 2002, Acambis announced that a bridging trial was planned for the first half of 2003 to confirm that the vaccine produced by Berna was equivalent to the typhoid vaccine that had been studied previously.
D000284:Administration, Oral; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012485:Salmonella typhi / Q000276:immunology*; D014435:Typhoid Fever / Q000276:immunology / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated